SUPN Q1 2022 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$153M+16.5% YoY

Gross Profit

$135M88.2% margin

Operating Income

$2M1.3% margin

Net Income

$26M16.8% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$811M

Stockholders' Equity

$828M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$153M	$131M	+16.5%
Gross Profit	$135M	$116M	+16.0%
Operating Income	$2M	$13M	-85.1%
Net Income	$26M	$6M	+349.9%

Revenue Segments

Product

$147M49%

Trokendi Xr

$63M21%

Oxtellar X R

$28M9%

GOCOVRI

$23M8%

APOKYN

$18M6%

Qelbree

$8M3%

Manufactured Product, Other

$8M3%

Royalty

$5M2%